
Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast said it was highlighted at the ASX Investor Day in Melbourne during a session titled “Meet the CEO: Inside Australia’s
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MEOBF | Mesoblast Limited | 1.14 | -0.16 | -12.22% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.14 | -12.22% |

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast said it was highlighted at the ASX Investor Day in Melbourne during a session titled “Meet the CEO: Inside Australia’s

Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. Mesoblast Limited is described as a global leader in allogeneic cellular medicines for inflammatory diseases. The November 2026 ASX Investor Day

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited is named in the notice, but the release does not provide information about its industry, primary products

Mesoblast Limited ( ($AU:MSB) ) has shared an update. Mesoblast Limited reported that all resolutions at its annual general meeting on 10 November 2026 were decided by poll and carried.

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast reported that it completed enrollment in a pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain,

The latest update is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast, a developer of allogeneic, off-the-shelf cellular medicines for severe inflammatory conditions, said it is expanding operational management around

Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast Limited filed a final director’s interest notice for William Burns, who ceased to be a director on 10 November 2026.

Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast Limited submitted a final director interest notice for Dr Eric Rose, identifying 10 November 2026 as the date he ceased

Mesoblast Limited ( ($AU:MSB) ) has issued an update. Mesoblast hosted a webinar featuring pediatric transplant specialist Dr. Susan Prockop, who discussed Ryoncil as a treatment paradigm for acute graft-versus-host

Mesoblast (MESO) announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $1.53B | $-0.02 | $72.75M | 0.61 | -26.11 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.